| Literature DB >> 34072717 |
Sakshi Bajaj1, Shivkanya Fuloria2, Vetriselvan Subramaniyan3, Dhanalekshmi Unnikrishnan Meenakshi4, Sharad Wakode1, Avneet Kaur5, Himangini Bansal1, Satish Manchanda1, Sachin Kumar1, Neeraj Kumar Fuloria2.
Abstract
Swertia alata C.B Clarke (Gentianaceae) is a well-reported plant in the traditional system of medicine. The present study was intended to isolate the phytoconstituents from the ethanolic extract of the aerial parts of S. alata; and evaluate for in vitro COX-1/COX-2 inhibition activity, in vivo anti-inflammatory and ulcerogenic activity. Phytoisolation involved partitioning of S. alata ethanolic extract into petroleum ether and chloroform soluble fractions using silica gel-based column chromatography. The isolation afforded two phytoisolates, namely oleanolic acid (SA-1) and 3-hydroxylup-12-(13)-ene-17-carboxylic acid (SA-4). Phytoisolates structures were established by melting point, ultraviolet (UV), attenuated total reflection-Fourier-transform infrared (ATR-FTIR), nuclear magnetic resonance (1H-NMR, 13C-NMR and HMBC) and mass spectrometry. Phytoisolates were further evaluated for in vitro cyclooxygenase (COX-1/COX-2) inhibitory activity, in vivo anti-inflammatory and ulcerogenic activity. The study revealed SA-4 (COX-1/COX-2 inhibition activity of 104/61.68 µM with % inhibition of 61.36) to be more effective than SA-1 (COX-1/COX-2 inhibition activity of 128.4/87.25 µM, with % inhibition of 47.72). SA-1 and SA-4, when subjected to ulcerogenic study, exhibited significant gastric tolerance. The current study reports chromatographic isolation and spectrometric characterization of SA-1 and SA-4. The present study concludes that compound SA-4 possess significant anti-inflammatory activity and less irritant property over gastric mucosa with no significant ulcerogenicity in comparison to indomethacin.Entities:
Keywords: Swertia alata; anti-inflammatory; chromatography; partitioned; spectrometry; ulcerogenic
Year: 2021 PMID: 34072717 PMCID: PMC8229181 DOI: 10.3390/plants10061109
Source DB: PubMed Journal: Plants (Basel) ISSN: 2223-7747
Figure 1The chemical structures of (a) SA-1; and (b) SA-4.
1HNMR and 13CNMR data for compound SA-1.
| Position | 1H NMR | 13C NMR |
|---|---|---|
| 1 | 1.18, m, 2H | 29.26 |
| 2 | 1.79, m, 2H | 29.61 |
| 3 | 3.56, m, 1H | 29.38 |
| 4 | -- | 77.02 |
| 5 | 1.18, m, 1H | 29.26 |
| 6 | 1.42, m, 2H | 29.38 |
| 7 | 1.18, t, 2H ( | 29.26 |
| 8 | -- | 33.75 |
| 9 | 2.13, t, 1H ( | 35.24 |
| 10 | -- | 29.61 |
| 11 | 2.30, d, 2H ( | 35.32 |
| 12 | 5.21, t, 1H ( | 125.77 |
| 13 | -- | 127.28 |
| 14 | -- | 35.46 |
| 15 | 1.89, t, 2H ( | 29.61 |
| 16 | 2.5, t, 2H ( | 24.71 |
| 17 | -- | 35.52 |
| 18 | 2.27, t, 1H ( | 35.62 |
| 19 | 1.18, t, 2H ( | 29.26 |
| 20 | -- | 31.94 |
| 21 | 1.18, m, 2H | 29.26 |
| 22 | 2.13, t, 2H ( | 23.76 |
| 23 | 0.4, s, 3H | 14.1 |
| 24 | 0.45, s, 3H | 14.1 |
| 25 | 0.52, s, 3H | 22.71 |
| 26 | 0.78, s, 3H | 29.06 |
| 27 | 0.81, s, 3H | 29.06 |
| 28 | -- | 178.33 |
| 29 | 0.47, s, 3H | 24.71 |
| 30 | 0.47, s, 3H | 24.71 |
Note: Coupling constants in Hertz are provided in parenthesis.
Figure 2HMBC interaction in (a) SA-1 (b) SA-4.
1HNMR and 13CNMR data of compound SA-4.
| Position | 1H NMR | 13CNMR |
|---|---|---|
| 1 | 1.18, m, 2H | 27.2 |
| 2 | 1.70, m, 2H | 27.96 |
| 3 | 3.72, m, 1H | 72.53 |
| 4 | -- | 27.82 |
| 5 | 1.18, m, 1H | 27.2 |
| 6 | 1.45, m, 2H | 27.82 |
| 7 | 1.18, m, 2H | 27.2 |
| 8 | -- | 33.25 |
| 9 | 1.18, m, 1H | 35.28 |
| 10 | -- | 27.96 |
| 11 | 2.13, t, 2H ( | 35.32 |
| 12 | 5.20, t, 1H ( | 125.42 |
| 13 | -- | 127.35 |
| 14 | -- | 35.46 |
| 15 | 1.18, m, 2H | 27.96 |
| 16 | 1.70, m, 2H | 24.97 |
| 17 | -- | 35.52 |
| 18 | 2.23, d, 1H ( | 35.62 |
| 19 | 1.56, m, 1H | 51.63 |
| 20 | 1.90, d 2H, ( | 35.62 |
| 21 | 1.96, d, 2H, ( | 35.92 |
| 22 | 0.81, s, 3H | 17.97 |
| 23 | 0.85, s, 3H | 17.97 |
| 24 | 0.95, m, 3H | 24.97 |
| 25 | 0.95, m, 3H | 18.01 |
| 26 | 0.95, m, 3H | 27.2 |
| 27 | -- | 27.2 |
| 28 | 1.56, m, 1H | |
| 29 | 0.65, d, 3H ( | 17.97 |
| 30 | 0.65, d, 3H ( | 17.97 |
Note: Coupling constants in Hertz are provided in parenthesis.
IC50 of the synthesized compounds by in vitro COX-1 and COX-2 enzymatic assay and COX-2.
| Position | IC50 (µM) | |
|---|---|---|
| COX-1 | COX-2 | |
| SA-1 | 128.4 | 87.25 |
| SA-4 | 104 | 61.68 |
| Indomethacin | 53 | 36.56 |
Note: C50 value is the concentration of the compound required to produce 50% of inhibition of COX-1 and COX-2 respectively using enzyme immuno-assay kit (Catalog No. 560131, Cayman Chemicals, Inc., Ann Arbor, MI, USA).
In vivo anti-inflammatory activity of compounds using carrageenan-induced rat paw edema method.
| Compound | Increase in Paw Edema (mL) a,b | |
|---|---|---|
| SA-1 | 2 mg/kg | 0.29 ± 0.00 |
| 4 mg/kg | 0.27 ± 0.22 | |
| 8 mg/kg | 0.23 ± 0.01 | |
| SA-4 | 2 mg/kg | 0.28 ± 0.00 |
| 4 mg/kg | 0.26 ± 0.22 | |
| 8 mg/kg | 0.17 ± 0.01 | |
| Control | 0.44 ± 0.04 | |
| Indomethacin | 0.15 ± 0.02 | |
Note: p-values were compared with the control group (3 h after inducing edema) (Tukey’s test). Number of animals (rats) in each group = 5. a Values are determined after 3 h and are expressed as Mean ± SEM. b p < 0.05 (significant difference).
In vivo ulcerogenic activity of the compounds in rat model.
| Compound | Ulcerogenic Activity a | |
|---|---|---|
| SA-1 | 6 mg/kg | 0.0 ± 0.00 |
| 12 mg/kg | 0.0 ± 0.00 | |
| 24 mg/kg | 2.5 ± 0.61 | |
| SA-4 | 6 mg/kg | 0.0 ± 0.00 |
| 12 mg/kg | 1.8 ± 0.44 | |
| 24 mg/kg | 2.1 ± 0.44 | |
| Control | 0.0 ± 0.00 | |
| Indomethacin | 2.7 ± 0.27 | |
Note: a Number of animals in each group is 5. b Severity Index = mean score of treated group and mean score of control group. c p < 0.5 (significant difference).
Figure 3Macroscopic observation of gastric mucosal lesions in the ulcer model; (a) Indomethacin (21 mg/kg); (b) control; (c) SA-4 (12 mg/Kg); (d) SA-4 (24 mg/kg); (e) SA-1 (24 mg/Kg).
Figure 4Flowchart representing the extraction and isolation of phytoisolates from S. alata extract using various fractions of chloroform and petoleum ether as eluent.